William Sikov, MD
Hematology & Oncology · Providence, RINPI 1811916661
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $123,025 of the $155,979 with a category attached, or 78.9%. 10 manufacturers reported payments, led by Lilly USA, LLC at 48.5% of the total. Reporting peaked in 2022 at $50,668 and has fallen 96.5% since, to $1,759 in 2024. Among hematology & oncology clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 174 payments — averaging $896.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$76K
- Seagen Inc.$33K
- Daiichi Sankyo Inc.$27K
- Eisai Inc.$10K
- AstraZeneca$5K
- Gilead$3K
- plus $2K from 4 others
Across 53 payments — averaging $4207.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$129K
- Eli Lilly$46K
- F. Hoffmann-la Roche AG$23K
- AbbVie$15K
- Pfizer$10K
What the payments were for
- Consulting fees$18,60012%
- Speaking & faculty fees$123,02579%
- Travel & lodging$10,3177%
- Food & beverage$4,0103%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 87 | $75,623 |
| Seagen Inc. | 29 | $32,868 |
| Daiichi Sankyo Inc. | 26 | $27,404 |
| Eisai Inc. | 6 | $9,586 |
| AstraZeneca | 7 | $4,938 |
| Gilead | 3 | $3,218 |
| Astrazeneca UK Limited | 11 | $1,683 |
| Genentech, Inc. | 3 | $563 |
| Foundation Medicine, Inc. | 1 | $66 |
| Stemline Therapeutics Inc. | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$155,979 in reported general payments places this provider in the 95th percentile of 68 hematology & oncology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Providence
- Ritesh RathoreProvidence$148K
- Anthony MegaProvidence$65K
- Adam OlszewskiProvidence$63K
- Hina KhanProvidence$34K
- Peter BarthProvidence$29K
- Thomas OllilaProvidence$19K
- John ReaganProvidence$18K
- Jennifer GassProvidence$16K
- Matthew HadfieldProvidence$10K
- Humera KhurshidProvidence$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.